On February 21, 2023, which is also the second day of the second lunar month "dragon head", Jiangxi Tianxu Pharmaceutical Co., LTD., a wholly-owned subsidiary of Minsheng Technology Co., Ltd. also received the first API approval -- propyl thio-isoniacinamide. This approval will open up new growth space for the company.

Protionamide is an anti-tuberculosis drug, which has strong inhibitory effect on mycobacterium tuberculosis. Clinically, it is often used in combination with streptomycin, isoniazid or rifampicin, which can not only enhance the curative effect, but also delay the development of drug resistance.

Indications: It is only effective against mycobacterium, and is used in combination with other antituberculosis drugs for tuberculosis patients who have not been treated by first-line drugs (e.g., streptomycin, isoniazid, rifampicin and ethambutol).

Jiangxi Tianxu Pharmaceutical Co., Ltd. was founded in November 2012, formerly known as Jiangxi Tianxu Chemical Co., LTD. In 2016, it was officially renamed as Jiangxi Tianxu Pharmaceutical Co., LTD., with a registered capital of 100 million yuan, it is located in Yihuang County Industrial Park, Fuzhou City, Jiangxi Province. It is a high-tech enterprise integrating the research and development, production and sales of apis, pharmaceutical intermediates, veterinary drug intermediates, pesticide intermediates and chemical apis.

Day xu-gou pharmaceutical company's main products include: pesticide intermediates 2, 3 - dichloro pyridine, 2-3 - chloro - pyridine hydrazine group and (R) - (+) - 2 - (4 - hydroxyl phenoxy) propionic acid, (R) - (+) - 2 - (4 - hydroxyl phenoxy) propionic acid methyl ester; Veterinary intermediate D-p-sulfoxyl phenylserine ethyl ester; Pharmaceutical intermediate 2-amino-4, 6-dichloro-5-formylaminopyrimidine (FADCP); Pharmaceutical raw materials such as propyl thioisonicotinamine and ethyl thioisonicotinamine.